等待开盘 04-01 09:30:00 美东时间
+0.670
+3.83%
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59
Goldman Sachs analyst James Yaro maintains Perella Weinberg (NASDAQ:PWP) with a Sell and lowers the price target from $21.5 to $18.5.
03-13 01:41
今日重点评级关注:瑞杰金融:上调Lumexa Imaging Holdings评级至"强力买入",目标价23美元;BTIG:维持Transocean"买入"评级,目标价从6美元升至10美元
02-10 10:29
Keefe, Bruyette & Woods analyst Michael Brown maintains Perella Weinberg (NASDAQ:PWP) with a Market Perform and raises the price target from $20 to $23.
02-09 22:29
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Perella Weinberg Partners业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年全年营收7.51亿美元,同比下降14%,但仍为公司20年历史中第三高营收水平 - 第四季度营收2.19亿美元,其中包含1,850万美元来自2026年1月初完成但按会计准则计入Q4的交易收入 - 欧洲业务实现历史最高年度营收,重组业务同样创下营收纪录 **成本控制:** - 调整后非薪酬支出1.59亿美元,同比下降2%,低于公司年初预期的个位数增长 - 成本控制表现优于预期 **现金状况:** - 年末现金
02-07 12:31
Perella Weinberg (NASDAQ:PWP) released its Q4 earnings on Friday, February 6, 2...
02-06 20:02
Companies Reporting Before The Bell • Biogen (NASDAQ:BIIB) is estimated to repo...
02-06 19:11
Perella Weinberg (NASDAQ:PWP) will release its quarterly earnings report on Fri...
02-06 00:00
Perella Weinberg Partners (PWP) plans to release its 2025 full-year and Q4 financial results on February 6, 2026, before the market opens. A conference call and webcast to review the results will be held at 9:00 AM ET on the same day. The webcast will be accessible via the Investors section of PWP's website at https://investors.pwpartners.com. A replay will be available two hours after the live call through February 13, 2026. PWP is a leading glo...
01-28 13:51
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54